{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T21:28:44Z","timestamp":1749072524298,"version":"3.33.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.msard.2023.104865","type":"journal-article","created":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T21:22:39Z","timestamp":1688332959000},"page":"104865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination"],"prefix":"10.1016","volume":"77","author":[{"given":"Amir","family":"Labani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasra","family":"Kaviani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Ropero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharine","family":"Russman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2727-547X","authenticated-orcid":false,"given":"Daniel","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104865_bib0001","doi-asserted-by":"crossref","unstructured":"Achiron A., Dolev M., Menascu S., Et Al. 2021 Covid-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Multiple sclerosis (Houndmills, Basingstoke, England). https:\/\/pubmed.ncbi.nlm.nih.gov\/33856242\/.","DOI":"10.1177\/13524585211003476"},{"issue":"12","key":"10.1016\/j.msard.2023.104865_bib0002","article-title":"Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis","volume":"9","author":"Achtnichts","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.msard.2023.104865_bib0003","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-COV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","volume":"27","author":"Apostolidis","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2023.104865_bib0004","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-COV-2 vaccine","author":"Baden","year":"2021","journal-title":"The New England Journal of Medicine"},{"author":"Barzegar","key":"10.1016\/j.msard.2023.104865_bib0005"},{"key":"10.1016\/j.msard.2023.104865_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.3599","article-title":"Humoral and T-cell response to SARS-COV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab","author":"Brill","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2023.104865_bib0007","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM200102013440501","article-title":"Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group","author":"Confavreux","year":"2001","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.msard.2023.104865_bib0008","unstructured":"Czarnowska A., Tarasiuk J., Zajkowska O., Et Al. 2022 Safety of vaccines against SARS-COV-2 among Polish patients with multiple sclerosis treated with disease-modifying therapies. MDPI. https:\/\/www.mdpi.com\/2076-393X\/10\/5\/763. Published May 12, 2022."},{"key":"10.1016\/j.msard.2023.104865_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2021-327200","article-title":"mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis","author":"Di Filippo","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.msard.2023.104865_bib0009","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000991","article-title":"Vaccine hesitancy in patients with multiple sclerosis: preparing for the SARS-COV-2 vaccination challenge","author":"Diem","year":"2021","journal-title":"Neurology neuroimmunology &"},{"key":"10.1016\/j.msard.2023.104865_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120155","article-title":"Covid-19 vaccination in patients with multiple sclerosis: safety and humoral efficacy of the third booster dose","author":"Dreyer-Alster","year":"2022","journal-title":"J. Neurol. Sci."},{"author":"Ehde","key":"10.1016\/j.msard.2023.104865_bib0012"},{"key":"10.1016\/j.msard.2023.104865_bib0013","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-011-5984-2","article-title":"Immunizations and risk of multiple sclerosis: systematic review and meta-analysis","author":"Farez","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104865_bib0014","doi-asserted-by":"crossref","unstructured":"Finsterer J. 2022 SARS-COV-2 triggered relapse of multiple sclerosis. Clin Neurol Neurosurg. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0303846722000919. Published March 14, 2022.","DOI":"10.1016\/j.clineuro.2022.107210"},{"author":"Garjani","key":"10.1016\/j.msard.2023.104865_bib0015"},{"key":"10.1016\/j.msard.2023.104865_bib0016","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-021-10648-w","article-title":"First Manifestation of multiple sclerosis after immunization with the pfizer-biontech COVID-19 vaccine","author":"Havla","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104865_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.796482","article-title":"B- and T-cell responses after SARS-COV-2 vaccination in patients with multiple sclerosis receiving disease modifying therapies: immunological Patterns and clinical implications","author":"Iannetta","year":"2022","journal-title":"Front Immunol"},{"author":"Jakimovski","key":"10.1016\/j.msard.2023.104865_bib0018"},{"key":"10.1016\/j.msard.2023.104865_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.5109","article-title":"Immunogenicity and safety of a third SARS-COV-2 vaccine dose in patients with multiple sclerosis and weak immune response after COVID-19 vaccination","author":"K\u00f6nig","year":"2022","journal-title":"JAMA Neurol"},{"author":"Kataria","key":"10.1016\/j.msard.2023.104865_bib0019"},{"author":"Katz","key":"10.1016\/j.msard.2023.104865_bib0020"},{"key":"10.1016\/j.msard.2023.104865_bib0021","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-021-10780-7","article-title":"Covid-19 mRNA vaccination leading to CNS inflammation: a case series","author":"Khayat-Khoei","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104865_bib0022","doi-asserted-by":"crossref","DOI":"10.1002\/ana.26346","article-title":"Cellular and humoral immunity to SARS-COV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study","author":"Kister","year":"2022","journal-title":"Ann. Neurol."},{"author":"Levit","key":"10.1016\/j.msard.2023.104865_bib0024"},{"author":"Maglione","key":"10.1016\/j.msard.2023.104865_bib0025"},{"key":"10.1016\/j.msard.2023.104865_bib0026","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-016-8263-4","article-title":"Vaccines and multiple sclerosis: a systematic review","author":"Mailand","year":"2017","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.msard.2023.104865_bib0027","doi-asserted-by":"crossref","DOI":"10.1177\/20552173221102067","article-title":"Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis","author":"Marrie","year":"2022","journal-title":"Multiple Sclerosis Journal-Experimental, Translational, and Clinical"},{"key":"10.1016\/j.msard.2023.104865_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.868915","article-title":"Humoral and cellular immune responses to SARS-COV-2 mRNA vaccination in patients with multiple sclerosis: an Israeli multi-center experience following 3 vaccine doses","author":"Milo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.msard.2023.104865_bib0029","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2200674","article-title":"Safety and efficacy of a third dose of BNT162B2 covid-19 vaccine","author":"Moreira","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.msard.2023.104865_bib0030","doi-asserted-by":"crossref","unstructured":"Moser T., O'Sullivan C., Otto F., et\u00a0al. Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study. Therapeutic Advances in Neurological Disorders. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9036387\/. Published April 22, 2022.","DOI":"10.1177\/17562864221092092"},{"key":"10.1016\/j.msard.2023.104865_bib0031","doi-asserted-by":"crossref","unstructured":"Moser T., Otto F., O'Sullivan C., et\u00a0al. Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-cd20 medications - a pilot study. Multiple Sclerosis and Related Disorders. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8785406\/. Published March 2022.","DOI":"10.1016\/j.msard.2022.103560"},{"key":"10.1016\/j.msard.2023.104865_bib0032","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162B2 mRNA Covid-19 vaccine","author":"Polack","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.msard.2023.104865_bib0033","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","author":"Sadoff","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.msard.2023.104865_bib0034","doi-asserted-by":"crossref","unstructured":"Schwarz T., Otto C., Jones T.C., Et Al. 2022 Preserved T cell responses to SARS-COV-2 in anti-cd20 treated multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). https:\/\/pubmed.ncbi.nlm.nih.gov\/35575234\/.","DOI":"10.1101\/2021.10.11.21264694"},{"author":"Skori\u0107","key":"10.1016\/j.msard.2023.104865_bib0035"},{"author":"Tallantyre","key":"10.1016\/j.msard.2023.104865_bib0036"},{"key":"10.1016\/j.msard.2023.104865_bib0037","doi-asserted-by":"crossref","DOI":"10.1002\/ana.26251","article-title":"Covid-19 vaccine response in people with multiple sclerosis","author":"Tallantyre","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.104865_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577785","article-title":"New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure","author":"Toljan","year":"2022","journal-title":"J. Neuroimmunol."},{"author":"Tortorella","key":"10.1016\/j.msard.2023.104865_bib0039"},{"key":"10.1016\/j.msard.2023.104865_bib0040","doi-asserted-by":"crossref","unstructured":"Uhr L., Mateen F.J. 2022 Covid-19 vaccine hesitancy in multiple sclerosis: a cross-sectional survey. Multiple sclerosis (Houndmills, Basingstoke, England). https:\/\/pubmed.ncbi.nlm.nih.gov\/34313513\/.","DOI":"10.1177\/13524585211030647"},{"author":"Yap","key":"10.1016\/j.msard.2023.104865_bib0041"},{"key":"10.1016\/j.msard.2023.104865_bib0042","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-022-06051-6","article-title":"Covid-19 vaccines and patients with multiple sclerosis: willingness, unwillingness and hesitancy: a systematic review and meta-analysis","author":"Yazdani","year":"2022","journal-title":"Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482300367X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482300367X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T14:09:43Z","timestamp":1737641383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482300367X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":42,"alternative-id":["S221103482300367X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104865","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104865"}}